3-(4-Methoxyphenyl)-5-({[4-(4-Methoxyphenyl)-5-Methyl-4h-1,2,4-Triazol-3-Yl]sulfanyl}methyl)-1,2,4-Oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-Methoxyphenyl)-5-({[4-(4-Methoxyphenyl)-5-Methyl-4h-1,2,4-Triazol-3-Yl]sulfanyl}methyl)-1,2,4-Oxadiazole
• 英文别名: 3-(4-methoxyphenyl)-5-[[4-(4-methoxyphenyl)-5-methyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,2,4-oxadiazole
• 化学式: C₂₀H₁₉N₅O₃S
• 分子量: 409.5
• InChiKey: LQZSHPITKSPDLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  113
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• WNT SIGNALING INHIBITOR
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20160168125A1

  公开（公告）日：2016-06-16

  A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n 1A represents 0 or 1; n 2A and n 3A may be the same or different, and each represents 1 or 2; R OA represents optionally substituted aryl or the like; R 2A represents a hydrogen atom or the like; R 3A represents an optionally substituted aromatic heterocyclic group or the like; X 1A , X 2A , X 3A and X 4A each represent CH or the like; Y 1A represents CH 2 or the like; Y 2A represents N or the like; and L A represents CH 2 or the like).

  提供一种Wnt信号抑制剂，其包括以下式（IA）所表示的融合环杂环化合物作为活性成分或其药学上可接受的盐等：（其中，n1A表示0或1；n2A和n3A可以相同也可以不同，每个表示1或2；ROA表示可选择地取代的芳基或类似物；R2A表示氢原子或类似物；R3A表示可选择地取代的芳香杂环基或类似物；X1A、X2A、X3A和X4A各自表示CH或类似物；Y1A表示CH2或类似物；Y2A表示N或类似物；LA表示 或类似物）。
• Wnt SIGNALING INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP3028703A1

  公开（公告）日：2016-06-08

  A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n1A represents 0 or 1; n2A and n3A may be the same or different, and each represents 1 or 2; R0A represents optionally substituted aryl or the like; R2A represents a hydrogen atom or the like; R3A represents an optionally substituted aromatic heterocyclic group or the like; X1A, X2A, X3A and X4A each represent CH or the like; Y1A represents CH2 or the like; Y2A represents N or the like; and LA represents CH2 or the like) .

  提供了一种 Wnt 信号转导抑制剂，其活性成分包括下式（IA）代表的融合环杂环化合物或其药学上可接受的盐等： (其中，n1A 代表 0 或 1；n2A 和 n3A 可以相同或不同，且各自代表 1 或 2；R0A 代表任选取代的芳基或类似物；R2A 代表氢原子或类似物；R3A 代表任选取代的芳族杂环基团或类似物；X1A、X2A、X3A 和 X4A 各自代表 CH 或类似物；Y1A 代表 CH2 或类似物；Y2A 代表 N 或类似物；以及 LA 代表 或类似物）。
• CELL AGGREGATION INCLUDING OLFACTORY NEURON OR PRECURSOR CELL THEREOF, AND METHOD FOR PRODUCING SAME
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP3842527A1

  公开（公告）日：2021-06-30

  A method for producing a cell cluster including an olfactory receptor neuron or a precursor cell thereof, comprising the following steps (1) to (3): step (1) of suspension-culturing a pluripotent stem cell in the presence of a Wnt signaling pathway inhibitory substance to form a cell aggregate; step (2) of suspension-culturing the cell aggregate obtained in the step (1) in the presence of a BMP signaling pathway-activating substance; and step (3) of suspension-culturing the cell aggregate obtained in the step (2) to obtain the cell cluster, wherein step (3) comprises at least one step selected from the group consisting of: step (3a) of suspension-culturing in the presence of an FGF signaling pathway-activating substance; step (3b) of suspension-culturing in the presence of a BMP signaling pathway inhibitory substance; and step (3c) of culturing in the presence of an FGF signaling pathway-activating substance and a BMP signaling pathway inhibitory substance.

  一种生产包括嗅觉受体神经元或其前体细胞的细胞团的方法，包括以下步骤(1)至(3)：步骤(1)在Wnt信号通路抑制物质存在下悬浮培养多能干细胞以形成细胞聚集体；步骤(2)在BMP信号通路激活物质存在下悬浮培养步骤(1)中获得的细胞聚集体；以及步骤(3)悬浮培养步骤(2)中获得的细胞聚集体以获得细胞簇，其中步骤(3)包括至少一个选自由以下组成的组的步骤：在 FGF 信号通路激活物质存在下进行悬浮培养的步骤(3a)； 在 BMP 信号通路抑制物质存在下进行悬浮培养的步骤(3b)；以及 在 FGF 信号通路激活物质和 BMP 信号通路抑制物质存在下进行培养的步骤(3c)。
• Antiviral axin stabilizer
  申请人：The Board of Regents for Oklahoma State University

  公开号：US10064862B2

  公开（公告）日：2018-09-04

  Methods and compositions for preventing and/or treating viral infections are provided. The methods involve administering an agent that stabilizes or enhances Axin1 activity, e.g. and agent that inhibits tankyrase. Administration of the agent stimulates or increases interferon activity, thereby preventing or lessening at least one symptom of virus infection. The virus infection may be caused by a respiratory virus such as influenza vims.

  提供了预防和/或治疗病毒感染的方法和组合物。这些方法包括施用稳定或增强 Axin1 活性的制剂，例如抑制 tankyrase 的制剂。给药可刺激或增加干扰素活性，从而预防或减轻病毒感染的至少一种症状。病毒感染可由呼吸道病毒引起，如流感病毒。
• Methods for treating diseases related to the wnt pathway
  申请人：Sandia Corporation

  公开号：US10624949B1

  公开（公告）日：2020-04-21

  The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

  本发明涉及治疗疾病的方法，其中疾病是由 Wnt 信号通路失调引起的。在某些情况下，可以通过施用抑制 Wnt 通路的化合物来治疗疾病。在其他情况下，该方法可选地包括进行全基因组筛选，以确定导致疾病状态降低的一个或多个基因，然后确定这些基因参与Wnt信号通路。